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This international multicenter study was designed to
evaluate the technical performance of the new double-
monoclonal, single-step Elecsys neuron-specific eno-
lase (NSE) enzyme immunoassay (EIA) and to assess
its utility as a sensitive and specific test for the diag-
nosis of small-cell lung cancer (SCLC). Intra- and inter-
assay coefficients of variation, determined in five con-
trol or serum specimens in six laboratories, ranged
from 0.7 to 5.3 (inter-laboratory median: 1.3%) and
from 1.3 to 8.5 (inter-laboratory median: 3.4%), respec-
tively. Laboratory-to-laboratory comparability was ex-
cellent with respect to recovery and inter-assay coeffi-
cients of variation. The test was linear between 0.0 and
320 ng/ml (highest measured concentration). There
was a significant correlation between NSE concentra-
tions measured using the Elecsys NSE and the estab-
lished Cobas Core NSE EIA II in all subjects (n = 723)
and in patients with lung cancer (n = 333). However,
NSE concentrations were systematically lower (ap-
proximately 9%) with the Elecsys NSE than with the
comparison test. Based on a specificity of 95% in com-
parison with the group suffering from benign lung dis-
eases (n = 183), the cut-off value for the discrimination
between malignant and benign conditions was set at
21.6 ng/ml. NSE was raised in 73.4% of SCLC patients
(n = 188) and was significantly higher (p < 0.01) in ex-
tensive (87.8%) as opposed to limited disease (56.7%).
NSE was also elevated in 16.0% of the cases with non-
small cell lung cancer (NSCLC, n = 374). It is concluded
that the Elecsys NSE EIA is a reliable and accurate di-
agnostic procedure for the measurement of NSE in
serum samples. The special merits of this new assay
are the wide measuring range (according to manufac-
turer’s declaration up to 370 ng/ml) and a short incu-
bation time of 18 min. Clin Chem Lab Med 2003; 41(1):
95–103
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Abbreviations: AUC, area under the curve, ECL, elec-
trochemiluminescence; ED, extensive disease; EGTM,
European Group on Tumor Markers; EIA, enzyme im-
munoassay; LD, limited disease; NSCLC, non-small cell
lung cancer; NSE, neuron-specific enolase; ROC, re-
ceiver-operating characteristic; SCLC, small-cell lung
cancer.
Introduction
Neuron-specific enolase (NSE) comprising γγ- and
αγ-isomers of the glycolytic enzyme enolase (2-phos-
pho-D-glycerate hydrolase E.C. 4.2.1.11) is expressed
preferentially in neuronal tissues and in amino precur-
sor uptake and decarboxylation cells (1, 2). The enzyme
was shown to be a valuable tumor marker for cancers
of neuroendocrine type such as small-cell lung cancer
(SCLC) (3–6), neuroblastoma (7), carcinoid tumors (8),
melanoma (9), seminoma (10), Merkel cell carcinoma
(11), medulloblastoma (12) or retinoblastoma (13). NSE
was further shown to be released into cerebrospinal
fluid and blood as a result of cerebral injury due to, for
instance, cardiac arrest (14), open heart surgery (15),
tonic-clonic seizures (16), status epilepticus (17), and
Creutzfeldt-Jakob disease (18).
In SCLC, which accounts to 20–25% of lung carcino-
mas, pre-treatment NSE was increased in 70–80% of
patients (2–6, 19, 20). In multivariate analyses, serum
NSE proved to be a prominent prognostic factor to-
gether with well-established ones such as performance
status and stage of the disease (20, 21). However, NSE
measurement is of doubtful utility for the monitoring of
chemo- and/or radiotherapy. It is true that NSE usually
decreases to the normal range in SCLC patients who re-
spond to chemotherapy but the decrease is irrespective
of the extent of remission (6, 22), therefore, NSE cannot
replace clinical response evaluations. Increasing NSE
levels may indicate tumor progression or recurrent dis-
ease (23, 24) but the lack of curative second-line treat-
ment limits the value of NSE measurement for this ap-
plication. Some years ago, Roche (Basel, Switzerland)
introduced the NSE enzyme immunoassay (EIA) on the
Cobas Core system as a two-step assay employing a
specific monoclonal antibody against NSE in conjunc-
tion with a polyclonal (rabbit) antibody. Clinical and
methodological features of this EIA were evaluated in
comparison with the NSE EIA developed by Boehringer*E-mail of the corresponding author: prof.ebert@t-online.de
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Mannheim, Mannheim, Germany on the Elecsys ES700
analyzer and NSE radioimmunoassay of Pharmacia
(Freiburg, Germany) (25). Further development of the
Cobas Core NSE EIA by the manufacturer resulted in a
one-step, solid- phase EIA employing two monoclonal
antibodies to NSE. The analytical performance and the
diagnostic utility of this Cobas Core NSE EIA II was eval-
uated in comparison with Cobas Core NSE EIA (26). The
particular test configuration of the Cobas Core NSE EIA
II has now been transferred to the Elecsys system by
Roche Diagnostics. The Elecsys system benefits from
chemiluminescence as the detection method that offers
a wide measuring range and short incubation times.
The aim of the present multicenter study was
1. to evaluate the technical performance of the new
Elecsys NSE test by assessing intra- and inter-assay
precision, dilution linearity and recovery;
2. to compare the results of NSE measurements using
the Elecsys NSE test with the established Cobas Core
NSE EIA II;
3. to establish clinical utility of the Elecsys NSE test as
a diagnostic tool in a series of patients with lung can-




Serum samples were taken before treatment from 562 con-
secutive patients with lung cancer admitted to Klinikum
Großhadern, Munich (laboratory 1), Thoraxklinik-Heidelberg
(laboratory 3) and Klinikum Gauting (laboratory 5) for diagno-
sis and therapy. Of these 562 patients, 188 suffered from SCLC
(mean age: 62, range: 35–86 years) and 374 from non-small
cell lung cancer (NSCLC) (mean age: 63, range: 34–86 years,
including patients with squamous cell carcinoma, adenocarci-
noma and with large cell carcinoma). 
The reference group consisted of 183 patients (mean age:
56, range: 21–85 years) with benign lung diseases of different
etiology including benign neoplasms. Diagnosis was per-
formed using standard protocols including histopathological
examination of biopsy material. 
The control group of 258 apparently healthy volunteers was
recruited exclusively from the employees of the clinics. The
stage of malignant disease was determined by clinical staging
after submitting the SCLC patients to the diagnostic protocol
following the classification of the Veterans Administration
Lung Cancer Group (VALG) as modified by Wolf and Have-
mann (27). Histological diagnosis was performed according to
the guidelines of the World Health Organization (28) and was
based on the predominant cell type. 
Elecsys® NSE
The Elecsys® NSE is a one-step, solid-phase enzyme im-
munoassay of a sandwich type. The assay employs two mon-
oclonal antibodies with different epitopes specific for γ-eno-
lase (named 18E5 and DN84B10) raised in mice immunized
with purified γ-enolase from human brain as described by
Sterk and coworkers (29). No crossreactivity against the α-
subunit has been found (29).
Patient specimens (sample volume: 20 µl), calibrators (Elec-
sys NSE CalSet) and controls (PreciControl Tumor Marker 1 and
2) are incubated with biotinylated monoclonal NSE-specific an-
tibody (NSE 18E5) and monoclonal NSE-specific antibody
(DN84B10) labeled with Tris(2,2’-bipyridyl)ruthenium(II)-com-
plex to form a sandwich complex. After addition of streptavidin-
labeled microparticles, the complex produced is bound to the
solid-phase via biotin-streptavidin interaction. First and second
incubation are performed at 37 °C. The reaction mixture is then
aspirated into the measuring cell where the microparticles are
magnetically captured onto the surface of the electrode. Un-
bound substances are removed with ProCell. The Elecsys NSE
immunoassay makes use of the electrochemiluminescence
(ECL)-technology. After application of voltage to the detection
cell electrode, a peak of light emission occurs over a short time
interval and can be detected as the resulting ECL-signal. A de-
fined area under the curve (AUC) is measured around the inten-
sity maximum. A lot-specific master calibration curve is estab-
lished at Roche Diagnostics using lot-specific test kit reagents
and master calibrators. The shape of the lot-specific master
curve is characterized by a four-parameter Rodbard function.
The data characterizing this curve are stored in the lot-specific
reagent barcode. Lot-specific assigned values of the calibrator
are read from the lot-specific master calibration curve and are
encoded on the calibrator barcode card. At the customer site,
the calibration results from two calibrators measured under
routine conditions are mathematically combined with the en-
coded data from the barcode. From this combination, the in-
strument determines lot calibration from which the concentra-
tion of measured samples is reliably calculated. The Elecsys
NSE immunoassay is standardized against the Enzymun NSE
immunoassay (Boehringer Mannheim, Mannheim, Germany).
The NSE tests were performed according to the procedure
specified by the manufacturer, Roche Diagnostics GmbH,
Mannheim, Germany. Total assay time amounts to 18 min.
The measuring range of the test is 0.05–370 ng/ml, defined by
the lower detection limit and the maximum of the master cal-
ibration curve.
The potential influence of several serum components on
NSE measurement was investigated by the manufacturer of
the test. There were no interferences by bilirubin (up to
72 mg/dl (1236 µmol/l)), triglycerides (up to 2000 mg/dl
(22.8 mmol/l)), biotin (up to 100 ng/ml (0.41 µmol/l)), rheuma-
toid factor (up to 1500 U/ml) and by frequently used therapeu-
tic drugs. No high dose hook effect at NSE concentrations of up
to 100000 ng/ml was observed. However, erroneous findings
may be caused by the human anti-mouse antibodies (HAMAs)
in patients who had been treated with monoclonal mouse anti-
bodies or who had received them for diagnostic purposes.
Elecsys NSE contains additives which minimize these effects.
In rare cases, interference due to extremely high titers of anti-
bodies to streptavidin and ruthenium may occur. The influence
of hemolysis on NSE testing is well documented.
Comparison test: Cobas Core NSE EIA II
The test principle of the reference Cobas Core NSE EIA II has
been previously described (26). Briefly, it is a one-step assay
using a highly specific monoclonal antibody to NSE (18E5)
immobilized on a polystyrene bead, in conjunction with a sec-
ond monoclonal NSE antibody (DN84B10) covalently linked to
horseradish peroxidase to form a sandwich with serum (or
calibrator or control) NSE. The assay is run in a one-point cal-
ibration mode using NSE recalibrator 50 ng/ml and a prede-
fined lot-specific master calibration curve.
Elecsys immunoassay analyzer
Elecsys NSE is intended for use on the Roche Elecsys
1010/2010 and ModularAnalytics E 170 immunoassay analyz-
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ers. In all instruments, electrochemiluminescence is em-
ployed as a higly sensitive detection method, offering a wide
measuring range and short incubation times. Elecsys 1010 is a
sample-selective multibatch analyzer for small to medium-
sized laboratories; Elecsys 2010 is a continuous analyzer for
medium to large-sized laboratories. The recently introduced
ModularAnalytics E 170 analyzer allows to combine the estab-
lished Elecsys technology with various other analytical units.
Intra-assay and inter-assay precision
For the assessment of intra-assay and inter-assay precision
the following specimens were used: PreciControl Tumor-
marker 1 (Lot 198815, mean concentration 12.4 ng/ml, range:
9.8–15 ng/ml, Roche Diagnostics), PreciControl Tumormarker
2 (Lot 198815, mean concentration 58.5 ng/ml, range:
46–71 ng/ml, Roche Diagnostics) and three human serum
samples with low (range: 5.7–8.7 ng/ml), medium (range:
11.5–35.8 ng/ml) and high (range: 93.3–212 ng/ml) NSE con-
centrations. The latter specimens were from serum pools
prepared at each site. For the assessment of intra-assay pre-
cision, the samples were measured 21 times within one run
at each site. For determination of the inter-assay precision,
the samples were measured in 21 independent runs at each
site.
Laboratory-to-laboratory variability and recovery
Precision and recovery were assessed in a ring trial using
three human serum pools distributed by Roche Diagnostics
(target values: 5.6, 14.4 and 96 ng/ml). Median recovery was
calculated from 10 independent runs at each site and com-
pared to the target value. 
Dilution linearity
Three human sera, containing NSE at a concentration
311.8 ng/ml (serum 1), 281.7 ng/ml (serum 2) and 317.8 ng/ml
(serum 3) were each measured undiluted and as solutions of
0.9 (serum) + 0.1 (diluent or serum), 0.8+0.2, 0.7+0.3, 0.6+0.4,
0.5+0.5, 0.4+0.6, 0.3+0.7, 0.2+0.8 and 0.1+0.9. Dilution was
performed using either the sample diluent from the Elecsys
test or human serum with low NSE concentration (9.75 ng/ml).
The measurements were done in duplicate in two indepen-
dent series to exclude possible dilution errors. NSE value of
9.75 ng/ml was subtracted to correct for the NSE content of
the diluent.
Comparison of the Elecsys NSE with Cobas Core NSE EIA II
To compare Elecsys NSE with established Cobas Core NSE
EIA II, NSE concentrations were measured simultaneously
with both methods at two sites (laboratory 1 and laboratory 3
in 723 serum samples drawn from a population consisting of
257 healthy individuals, 133 patients with benign lung dis-
eases, 104 patients with SCLC, and 229 patients with NSCLC).
Statistical methods
The results for the different groups studied are given as 5%,
50% (median), and 95% percentiles. Group comparisons were
analyzed descriptively using Wilcoxon’s nonparametric rank-
sum test (30). After careful inspection for possible outliers,
parametric descriptive statistics (mean, CV) was used to esti-
mate intra-assay and inter-assay precision. To protect against
outlying (influential) observations in the method comparison
analysis, the robust Passing and Bablok regression was used
(31, 32). The details of the differences between the two analyt-
ical methods are shown in a normalized differences plot. Dif-
Table 1 Elecsys NSE test: intra- and inter-assay coefficients of variation.
Intra-assay precision
Laboratory 1 Laboratory 2 Laboratory 3 Laboratory 4 Laboratory 5 Laboratory 6
Material Mean CV  Mean CV  Mean CV  Mean CV  Mean CV  Mean CV 
(ng/ml) % (ng/ml) % (ng/ml) % (ng/ml) % (ng/ml) % (ng/ml) %
PreciControl TM I 13.1 1.7 13.0 1.0 12.9 1.0 12.8 2.1 12.9 1.8 12.7 0.9
PreciControl TM II 62.6 2.2 60.5 0.7 61.9 1.0 61.5 1.8 60.6 2.0 60.3 1.2
Human Serum low 8.4 3.7 5.8 0.9 5.7 2.3 5.0 5.3 6.3 0.7 8.7 1.3
Human Serum medium 16.9 1.5 16.3 1.8 16.4 0.9 10.6 1.1 11.5 1.2 35.8 1.5
Human Serum high 165 1.0 149 1.3 116 4.1 118 1.3 93.8 1.2 212 1.1
Inter-assay precision
Laboratory 1 Laboratory 2 Laboratory 3 Laboratory 4 Laboratory 5 Laboratory 6
Material Mean CV  Mean CV  Mean CV  Mean CV  Mean CV  Mean CV 
(ng/ml) % (ng/ml) % (ng/ml) % (ng/ml) % (ng/ml) % (ng/ml) %
PreciControl TM I 12.2 3.6 12.5 3.6 13.4 1.8 12.4 3.4 12.7 1.6 13.0 3.3
PreciControl TM II 56.6 3.8 58.2 4.3 63.2 2.1 59.9 4.0 58.0 2.2 61.7 2.8
Human Serum low 8.7 3.4 4.9 8.5 5.7 1.3 5.1 7.6 6.2 4.7 8.5 2.4
Human Serum medium 17.3 6.6 16.0 2.9 16.2 2.0 10.2 2.8 11.4 2.4 35.4 3.0
Human Serum high 168 4.9 145 3.6 121 2.2 119 4.4 94.4 3.6 210 3.5
Intra- and inter-assay coefficients of variation (CVs) obtained
with the Elecsys NSE test in six laboratories. Specimens: Pre-
ciControl Tumormarker 1, PreciControl Tumormarker 2, and
three human serum samples with low (range: 5.7–8.7 ng/ml),
medium (range: 11.5–35.8 ng/ml) and high (range: 93.3–
212 ng/ml) NSE concentration.
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ferences between clinical groups are analyzed descriptively
by means of the (outlier) box plot and to account for the non-
normality of the data by means of the nonparametric
Wilcoxon rank-sum test (30). Diagnostic performance is de-
scribed in terms of sensitivity, specificity and AUC by receiver-
operating characteristic (ROC) analysis (33). Nonparametric
estimates have been used for the AUCs.
Results
The evaluation of precision and recovery
A summary of the results of intra-assay and inter-assay
precision evaluation of the Elecsys NSE test is shown in
Table 1. In the intra-assay precision study, CVs ranged
from 0.7 to 5.3%. The inter-assay CVs ranged from 1.3
to 8.5%. Table 2 gives recovery and CV data determined
at each site using serum pools distributed by Roche
Diagnostics (ring trial). Median recoveries calculated
from the data reported by the individual laboratories
were 5.5, 14.5 and 96.2 ng/ml, respectively. These val-
ues are in excellent agreement with the target values
assessed internally by Roche Diagnostics for pools
1–3: 5.6, 14.4 and 96 ng/ml, respectively. On the basis
of mean recoveries determined at each site, the me-
dian values for between-laboratory CVs were calcu-
lated for serum pools 1–3 and yielded 5.7, 4.2 and
4.3%, respectively.
Dilution linearity
The results of dilution linearity experiments are pre-
sented in Figures 1 and 2. In the series using sample
diluent, median recovery was 103.6% (mean: 106.6,
range: 85.8–140.3%). When serum was used as a dilu-
ent, median recovery was 106.4% (mean: 109.6, range:
98.1–130.3%). Irrespective of the nature of the diluent,
the deviation was highest in case of 1:10 dilution.
Elecsys NSE vs. Cobas Core NSE EIA II
The Passing-Bablok graphs for the comparison of Elec-
sys NSE with Cobas Core NSE EIA II are shown in Fig-
ure 3A (all samples) and Figure 4A (cancer patients).
The Passing-Bablok equation which includes all sam-
ples measured shows that the Elecsys NSE results
were on average 9.1% lower than these obtained using
Table 2 Ring trial: inter-assay CV and recovery of NSE in
three human serum pools.
Material Lab Min Max Mean Median CV%
Pool 1 1 5.1 5.5 5.4 5.4 2.2
2 5.3 5.8 5.5 5.6 3.0
Target: 3 5.8 6.0 5.9 5.9 1.1
5.6 ng/ml 4 5.4 6.0 5.6 5.5 4.1
5 5.6 5.8 5.7 5.7 1.1
6 4.9 5.3 5.1 5.1 2.6
Pool 2 1 13.7 14.5 14.0 13.9 2.0
2 13.5 15.1 14.4 14.5 3.7
Target: 3 15.1 15.9 15.5 15.4 1.5
14.4 ng/ml 4 13.4 15.6 14.4 14.0 5.2
5 14.6 15.3 14.9 14.9 1.4
6 13.2 14.4 14.0 14.1 3.4
Pool 3 1 87.3 94.6 92.2 92.7 2.4
2 88.1 103.3 94.6 95.6 4.9
Target: 3 100.6 107.7 103.3 103.7 2.3
96 ng/ml 4 87.2 105.8 93.0 90.5 6.9
5 97.1 101.9 99.0 99.0 1.4
6 88.5 97.9 93.8 95.5 4.0
Pools were measured 10 times each and were distributed by
Roche Diagnostics (Ring trial). CV is based on median values
of individual laboratories (Reagent lot No. 195768, Elecsys
2010 Instrument).
Figure 1 Test linearity assessed with three human serum
samples assayed in duplicate. Dilution was performed with
sample diluent. Each symbol represents an individual dilution
series.
Figure 2 Linearity assessed by measurements of three hu-
man serum samples assayed in duplicate. Dilution was per-
formed with serum with low NSE concentration (9.75 ng/ml).
This value was then subtracted to correct for the individual
values. Each symbol represents an individual dilution series.
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Cobas Core NSE EIA II. A similar result was obtained
when comparing only the samples from the cancer pa-
tients; in this case the values obtained with the Elecsys
NSE test were on average 8.4% lower. The two assays
correlated well with nonparametric Spearman’s rank
correlation coefficient 0.977 for both the total popula-
tion and the cancer patients. The normalized differ-
ences between both methods did not vary significantly
as a function of NSE concentration (Figure 3B, Fig-
ure 4B)
The very high degree of agreement between both
methods is also demonstrated by the ROC curves in
Figure 5.
Clinical evaluation
Distribution of the NSE concentrations measured with
the Elecsys NSE test in patients with untreated SCLC,
NSCLC, benign lung diseases and in healthy persons is
illustrated as Whisker plots in Figure 6. Listed in Table 3
are 5%, 50% and 95% percentiles and maximum values
of NSE concentrations. For SCLC, the values are further
stratified into Limited Disease (TNM I – IIIa) and Exten-
sive Disease (TNM IIIb/IV). The highest NSE concentra-
tions were obtained in patients with SCLC. The NSE
concentrations of the SCLC group differed significantly
from all the other groups (p < 0.001, Wilcoxon test).
There was also a significant difference in NSE con-
centrations between limited and extensive disease
(p < 0.001, Wilcoxon test).
Figure 7 presents the positivity rates of the Elecsys
NSE tests with respect to SCLC, the SCLC subgroups,
NSCLC and the group with benign lung diseases and
healthy persons. The positivity rates are based on a
cut-off value which corresponds to the 95% specificity
of the NSE test compared with the group with benign
lung diseases, following the criteria of the European
Working Group of Quality Control and Standardization
of Tumor Marker Assays (34). Based upon this speci-
ficity, the cut-off value was found to be 21.6 ng/ml. The
sensitivity of the Elecsys NSE test was 73.4% for total
SCLC and 56.7% for the Limited Disease subgroup and
87.8% for the Extensive Disease subgroup.
Figure 3A Correlation between NSE concentration mea-
sured by Elecsys NSE and Cobas Core NSE EIA II (Passing-
Bablok) in all studied subjects. Spearman’s rank correlation
coefficient rs: 0.977 (p < 0.001) (regression equation: Y =
0.924X –0.558; N = 723).
Figure 3B Normalized difference plot showing distribution
of differences between Elecsys NSE and Cobas Core NSE EIA
II methods as a function of NSE concentration in all subjects.
(Method X = Cobas Core NSE EIA, Method Y = Elecsys NSE
EIA).
Table 3 NSE concentration in patient groups.
NSE concentration (ng/ml)
N Min 5% 50% 95% Max
Apparently 258 2.5 6.2 9.7 16.6 32.3
healthy
Benign 183 4.1 5.9 11.6 21.6 60.7
SCLC 188 4.3 9.4 43.5 357.3 1053.5
LD* 60 4.8 8.8 25.3 217.1 748.0
ED* 90 4.3 12.0 74.9 370.0 770.0
NSCLC 374 2.1 5.4 13.1 38.6 355.0
Shown are the 5%, 50% (median), 95% percentiles and maxi-
mum values of NSE concentrations assessed by the Elecsys
NSE test in patients with SCLC, NSCLC, benign lung diseases
and in healthy persons. SCLC patients are further stratified
into limited and extensive disease (*staging not available in
38 cases).
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Discussion
The results of the precision and dilution linearity assess-
ment indicate that the new Elecsys NSE test is a reliable
and accurate diagnostic procedure for the measure-
ment of NSE concentrations in serum. Intra- and inter-
assay CVs were in the range 0.7–5.3% (median CV: 1.3%)
and 1.3–8.5% (median CV: 3.4%), respectively. In addi-
tion, it was shown that laboratory-to-laboratory compa-
rability was excellent with respect to recovery and CVs
calculated from the median recoveries obtained in the
individual laboratories. Intra- and inter-assay CVs for the
Elecsys NSE test are in the same order of magnitude as
those of reference Cobas Core NSE EIA II where intra-
and inter-assay CVs range from 2.1 to 4.6% and from 3.0
to 7.0%, respectively (26). They were clearly better than
those observed during the evaluation of Cobas Core
NSE EIA (25), where reported intra-assay CV was 11.7%
and inter-assay CV was 14.7%. It can be assumed that
the use of two monoclonal antibodies to NSE improves
the precision of the test. The lower inter-assay CVs of the
Elecsys NSE may be particularly important for disease
monitoring in SCLC because in the assessment of re-
sponse to therapy inter-assay CVs are used for the calcu-
Figure 4A Correlation between NSE concentrations mea-
sured by Elecsys NSE and Cobas Core NSE EIA II in the cancer
patients (Passing-Bablok). Spearman’s rank correlation coeffi-
cient rs: 0.977 (p < 0.001) (regression equation : Y = 0.906X
–0.725; N = 333).
Figure 4B Normalized difference plot showing distribution
of differences between Elecsys NSE and Cobas Core NSE EIA
II methods as a function of NSE concentration in cancer pa-
tients. (Method X = Cobas Core NSE EIA, Method Y = Elecsys
NSE EIA).
Figure 5 Receiver-operating characteristic curves of Elecsys
NSE and Cobas Core NSE EIA II methods for SCLC (sensitivity)
in relation to the reference group with benign lung diseases
(specificity). AUC Elecsys: 0.89; AUC Cobas Core: 0.91). Elec-
sys: —— Cobas Core: ——.
Figure 6 Distribution of NSE concentrations assessed by
Elecsys NSE in the various study groups. Data are presented
as multiple box and whisker plots showing median value (hor-
izontal line), mean value (x), upper and lower quartile and
range. Extreme values are plotted separately. Values greater
than 400 ng/ml are not shown. LD: limited disease, ED: exten-
sive disease.
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lation of the critical difference between two consecutive
marker levels (35). In our hands, the Elecsys NSE was lin-
ear up to a concentration of 320 ng/ml. The manufac-
turer claims that the analytical range of the Elecsys NSE
extends to 370 ng/ml. There was a significant correlation
between NSE concentrations measured using the Elec-
sys NSE and the established Cobas Core NSE EIA II, both
in all subjects and in patients with lung cancer. However,
the NSE concentrations measured by the new assay
were lower compared to those obtained by the Cobas
Core version of the assay. This was true for all investi-
gated groups.
NSE was raised in 73.4% of SCLC patients and was
significantly higher (p < 0.01) in extensive (87.8%) as op-
posed to limited disease (56.7%). This detection rate is
in accordance with the overwhelming majority of data
reported in the literature (3–6, 19, 20). The sensitivity of
73.4% is based on a cut-off level of 21.6 ng/ml, which
corresponds to the 95% specificity calculated from NSE
concentrations measured in the group with benign lung
diseases. The cut-off level of 21.6 ng/ml is considerably
higher than values observed in previous studies, which
ranged from 11.9 to 16.4 ng/ml (19, 25, 26). Although the
results of NSE measurement may differ with different
test versions, these discrepancies are mainly caused by
the differences in populations of individuals with be-
nign lung disorders, who are used for the calculation of
the cut-off point. The rather large number of 183 pa-
tients in this study allows a realistic view of the quality
of the NSE assay to discriminate between SCLC pa-
tients and those with benign lung diseases. We ob-
served rather high NSE concentrations in patients suf-
fering from (pleural) fibrosis (60.7 ng/ml), benign
paraganglioma (45.3 ng/ml), benign fibrous mesothe-
lioma (39.8 ng/ml) or tuberculosis (28.9 ng/ml,
32.2 ng/ml). In all these cases, hemolysis as a potential
explanation for elevated NSE levels was excluded. It is
well-known in clinical practice that patients with tuber-
culosis (or HIV infection) often have increased NSE con-
centration. In general, patients with alveolar infiltrates
or an interstitial pattern on chest X-ray had higher NSE
levels than those with normal radiographs (36). Direct
damage to the neural or neuroendocrine lung cells or a
degree of local hypoxia are likely to play a role in the in-
crease in NSE in these patients. Interestingly, NSE ele-
vation was reported as a frequent event in patients with
terminal hypoxia in the course of benign lung diseases
(37). In case of benign paraganglioma, elevated NSE
may not be uncommon since resected tumors reveal
vascular mass with nests of epithelial cells and the pres-
ence of neurosecretory granules (38).
Further potential application of NSE measurements
includes the differential diagnosis of malignant tumors
in the thoracic space. As was found in other studies, el-
evated NSE levels were observed in the various sub-
groups of NSCLC patients (16.0%) probably due to the
presence of small subpopulations differentiated as
small cells. It has been reported that 30–50% of bron-
chogenic carcinomas consist of heterogeneous cell
populations (39) but their histology is, as a rule, classi-
fied according to the dominating cell type (28). How-
ever, it would be interesting to know whether patients
with non-resectable NSCLC with elevated NSE would
benefit from chemotherapy. To our knowledge, such a
study has not been performed to date. Also, NSE is not
able to differentiate unequivocally between SCLC and
mediastinal tumors such as thymoma, teratoma and
Hodgkin’s and non-Hodgkin’s lymphomas. Elevated
NSE was also reported in 13.2% of the latter tumors
(40). This is of particular importance because both ma-
lignancies express similar roentgenographic features,
presenting with a hilar mass and mediastinal widening.
This means that the definite diagnosis can only be es-
tablished by biopsy.
Despite these limitations, NSE assays may be helpful
in the primary diagnosis of SCLC as was claimed by the
European Group on Tumor Markers (EGTM; 41). They
stated that NSE levels >25 ng/ml are suggestive of lung
cancer and NSE levels > 100 ng/ml are suggestive of
SCLC. In the present study it was found that 169 out of
the 562 patients with lung cancer (30.1%) had NSE lev-
els above 25 ng/ml. Of the 50 lung cancer patients with
NSE levels above 100 ng/ml, 44 suffered from SCLC
(23.4% of all SCLC patients) and six from NSCLC (1.6%
of all NSCLC patients). These figures are in good agree-
ment with the EGTM recommendations (40). However,
these findings also show that the definite diagnosis in
an individual patient cannot be made on the basis of
NSE level.
Conclusions
The new Elecsys NSE is a reliable test for the measure-
ment of serum NSE concentration showing high preci-
sion and good recovery and linearity. The test is distin-
guished by fast throughput, with the incubation time of
18 min. Its sensitivity with regard to SCLC is compara-
ble to the established Cobas Core NSE EIA II. NSE mea-
surement is a helpful diagnostic tool in patients in
whom invasive techniques cannot be used and in those
where diagnosis could not be made using standard
procedures.
Figure 7 Positivity rates (sensitivity) of the measurement of
NSE concentration with Elecsys NSE in the various study
groups. Cut-off value set at 21.6 ng/ml corresponds to the 95%
specificity of NSE measurement in patients with benign lung
diseases (34).
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